Adults 30 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Mobility as Measured by the Timed Up & Go (TUG)Primary· 12 months
The Timed Up \& Go (TUG) is a well-validated, brief measure of mobility. To complete this assessment, subjects sit in a standard arm chair and are instructed that when the team member says "Go", they should stand up from the chair, walk at their normal pace to a taped line, turn, walk back to their chair at a normal pace, and sit down again. The study team member will record the TUG results in seconds using a stopwatch. A lower TUG result indicates greater mobility. Scores at the pre- and post-intervention focus groups will be compared.
Baseline
Group
Value
95% CI
Arm 1
9.66
± 1.62
Arm 2
9.19
± 1.56
12-month
Group
Value
95% CI
Arm 1
10.9
± 1.67
Arm 2
10.03
± 2.2
Change in Overall Well-being as Measured by the Patient Global Impression of Change Scale (PGIC)Secondary· 12 months
The Patient Global Impression of Change Scale (PGIC) is a single-item rating scale that asks subjects to rate their overall response to the intervention using a 7-point rating scale, where 1 is "very much worse", 4 is "no change", and 7 is "very much improved". Percentages of subjects endorsing each of the 7 response options will be compared. This scale will be completed at the post-intervention focus group.
Group
Value
95% CI
Arm 1
5.47
± 1.18
Arm 2
5.75
± 1.14
Changes in Depression as Measured by the Hospital Anxiety and Depression ScaleSecondary· 12 months
The Hospital Anxiety and Depression Scale is a brief, 14-item highly validated scale for measuring anxiety (7 items) and depression (7 items), with each item scored 0-3, and reverse scoring for negatively framed items. Scores for each subscale are totaled and categorized as normal (0-7 points), borderline abnormal (8-10 points), and abnormal (11-21) points. Scores at the pre-intervention, 6-month, and 12-month study visits will be compared.
Baseline
Group
Value
95% CI
Arm 1
4.53
± 3.18
Arm 2
4.08
± 3.23
12 months
Group
Value
95% CI
Arm 1
3.59
± 2.62
Arm 2
2.92
± 2.94
Change in Quality of Life as Measured by the Parkinson's Disease Questionnaire- Short Form (PDQ-8)Secondary· 12 months
The Parkinson's Disease Questionnaire- Short Form (PDQ-8) is validated and shortened version of the PDQ-39, with 8 items each representing one domain of the PDQ-39, also with a summary index score standardized to a scale of 0-100, with higher scores signifying worse quality of life; this scale is recommended for use in PD by the Movement Disorder Society.
Baseline
Group
Value
95% CI
Arm 1
25.22
± 16.73
Arm 2
29.25
± 20.34
12-month
Group
Value
95% CI
Arm 1
20.67
± 13.66
Arm 2
21
± 17.58
Change in Cognitive Domains as Measured by Montreal Cognitive AssessmentSecondary· 12 months
A screening instrument designed to help health professionals detect mild cognitive dysfunction. Subjects will answer questions to measure different areas of cognition including attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible range is 0 (severely cognitively impaired) to 30 (perfect), where scores 26 and higher indicate normal cognition, and scores less than 26 indicate mild cognitive impairment or dementia.
Baseline
Group
Value
95% CI
Arm 1
25.88
± 2.66
Arm 2
26.67
± 3.14
12 months
Group
Value
95% CI
Arm 1
25.88
± 2.68
Arm 2
25.58
± 3.15
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The benefits of exercise for general health and well-being in older adults are well-established. Balance exercises such as tai chi and yoga, along with resistance training, can improve or maintain physical function in older adults and enhance muscle strength. Furthermore, aerobic activity is critical for maintaining and improving cardiovascular and functional health. Non-contact boxing has recently seen a surge in popularity among individuals with Parkinson's Disease (PD), with components of both aerobic and balance exercise. While participants anecdotally note improvements in stress and physical function, this has only been minimally studied. Therefore, we conducted a 10-week long pilot study of a structured karate exercise program. Among 15 participants, our pilot data highlights improvements in quality of life and high enthusiasm for the karate classes. Based on these promising results from the pilot, we are recruiting a larger, randomized group for the second phase of the karate intervention. The aim of this study is to test whether and to what degree a community-based karate class tailored for individuals with early- to middle-stage Parkinson's Disease (PD) 1) is feasible; 2) improves objective outcomes such as mobility and balance; 3) improves patient-reported outcomes compared with individuals given a standard exercise prescription for PD.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03555695 — Kick Out Parkinson's Disease- Karate Intervention
· NA
· completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Rush University Medical Center trials
Trials by the same sponsor.
NCT07278076 — Clinical Decision-Making During FEES: The Impact of Residue Amount and Location
· NA
· not yet recruiting
NCT07088120 — PRECISION-CPR: PRecision-Controlled Ventilation in CPR
· NA
· not yet recruiting
NCT06894719 — Oral Tranexamic Acid After Total Knee Arthroplasty
· Phase 4
· not yet recruiting
NCT06229392 — A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
· Phase 1
· withdrawn
NCT07452406 — Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rush University Medical Center
Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03882879.